Respiratory Infections

Ravina Kullar, PharmD, MPH, reflects on rapid advances in COVID-19 treatment understanding during IDWeek 2020.

The study population comprised 224 patients admitted to the ICU with influenza, and the overall rate of IPA was 3.1% (7/224).

New data highlight the need for more antimicrobial stewardship adoption in emergency care settings.

In an effort to expand serotype coverage beyond 13, a 20-valent pneumococcal conjugate vaccine, PCV20, is currently in development.

New data presented at IDWeek showed more than half observed households with a COVID-19 case reported a secondary infection, oftentimes within 3 days.

Phase 1 data and a history of benefit for worsening respiratory infections show promise for the therapy.

In a phase 1/2 randomized clinical trial, GlaxoSmithKline’s RSVPreF3 vaccine elicits a response.

A vaccine developer joins for a firsthand discussion on the development, research, and distribution process.

Cefiderocol was noninferior to high-dose, extended-infusion meropenem in terms of all-case mortality in patients with gram-negative nosocomial pneumonia and showed similar clinical and microbiological efficacy to best available therapies in carbapenem-resistant, gram-negative bacterial infections, according to 2 recently released studies.

A summary of new studies surrounding COVID-19 comorbid effects.

After a series of positive developments, the antiviral agent joins a quartet of candidates that failed to improve severely ill COVID-19 status in the Solidarity study.

A recently proposed effort toward herd immunity through younger person COVID-19 infection was met with contention from public health leaders and experts.

A 25-year-old male in Nevada was hospitalized due to a different SARS-CoV-2 strain 2 months after recovering from a first case.

Fundamental aspects of immunity to SARS-CoV-2 remain elusive. Here is an examination of some potential clues to protection.

A collection of expert perspectives on what the virus itself may mean for future crises.

New ACTT-2 data shows a marked benefit from the combination regimen versus lone remdesivir.

ACTT-1 findings for the Gilead antiviral show it improved chance of clinical improvement by 50% in very ill COVID-19 patients.

The new pathogen panel will distinguish between 20 different common and serious respiratory infections, giving clinicians more confidence in flu season diagnoses.

A pair of investigative monoclonal antibodies from Lilly show promise for mitigating mild to moderate COVID-19 risks of escalation.

Fauci also shares suggestions for college campus to mitigate community-based spread while classes continue.

The President's hospital stay continues through a third day, with conflicting messages on his health and an escalation in therapy.

A discussion with an expert on the particularities of the vaccines, which vary in temperature climate requirements and dosages.

A collection of perspectives on how the virus is affecting patients outside of infectious disease.

Why the AstraZeneca & Oxford University trial's pause due to an adverse event was a sign to Fauci the vaccine monitoring systems are working.